Skip to main content
SpringerLink
Log in

Interaction between co-morbidities and cancer survival

  • CORRESPONDENCE
  • Published:
European Journal of Epidemiology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Nagel G, Peter R, Braig S, Hermann S, Rohrmann S, Linseisen J. The impact of education on risk factors and the occurrence of multimorbidity in the EPIC-Heidelberg cohort. BMC Public Health. 2008;8:384. https://doi.org/10.1186/1471-2458-8-384.

    Article  PubMed  PubMed Central  Google Scholar 

  2. El-Shami K, Oeffinger KC, Erb NL, et al. American cancer society colorectal cancer survivorship care guidelines. CA Cancer J Clin. 2015;65(6):428–55. https://doi.org/10.3322/caac.21286.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Baade PD, Fritschi L, Eakin EG. Non-cancer mortality among people diagnosed with cancer (Australia). Cancer Causes Control. 2006;17(3):287–97. https://doi.org/10.1007/s10552-005-0530-0.

    Article  PubMed  Google Scholar 

  4. van Erning FN, van Steenbergen LN, Lemmens V, et al. Conditional survival for long-term colorectal cancer survivors in the Netherlands: who do best? Eur J Cancer. 2014;50(10):1731–9. https://doi.org/10.1016/j.ejca.2014.04.009.

    Article  PubMed  Google Scholar 

  5. Badrick E, Sperrin M, Buchan IE, Renehan AG. Obesity paradox and mortality in adults with and without incident type 2 diabetes: a matched population-level cohort study. BMJ Open Diabetes Res Care. 2017;5(1):e000369. https://doi.org/10.1136/bmjdrc-2016-000369.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by CRUK via the funding to Cancer Research UK Manchester Centre: [C147/A18083] and [C147/A25254]. AGR is supported by the Manchester NIHR Biomedical Research Centre [IS-BRC-1215-20007].

Author information

Authors and Affiliations

  1. Division of Cancer Sciences, Manchester Academic Health Science Centre, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

    Andrew G. Renehan & Nasra N. Alam

  2. Manchester Cancer Research Centre, National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester, UK

    Andrew G. Renehan & Nasra N. Alam

  3. Health eResearch Centre, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

    Matthew Sperrin

Authors
  1. Andrew G. Renehan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nasra N. Alam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew Sperrin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AGR and MS conceived the project. AGR and MS are the joint principal investigators for the study. NNA is the clinical research fellow and is responsible for management of the project. All authors critically revised the manuscript. All authors confirm that they meet ICMJE criteria for authorship.

Corresponding author

Correspondence to Andrew G. Renehan.

Ethics declarations

Conflict of interest

AGR has received lecture honoraria from Merck Serona and Janssen-Cilag, and independent research funding and lecture honoraria from Novo Nordisk and Sanofi Pasteur MSD. All other authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Renehan, A.G., Alam, N.N. & Sperrin, M. Interaction between co-morbidities and cancer survival. Eur J Epidemiol 34, 1103–1105 (2019). https://doi.org/10.1007/s10654-019-00547-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10654-019-00547-w

Search

Navigation